Group Medical Visits for Patients With Dyslipidemia

NCT07543718 · tracked via the Priya Life Science Canada tracker

Sponsor

Université de Sherbrooke

Phase

Not applicable

Started

2026-04

Last updated

2026-04-22

Condition(s) studied

Dyslipidemias

Investigational drug(s) / intervention(s)

Group medical visits

Group medical visits: Group medical visits are designed to improve knowledge of participants and promote self-management.

Study summary

Physicians' interventions to promote the improvement of lifestyle habits have been shown to be effective. However, such interventions remain underutilized due to barriers such as lack of time, confidence, and compensation. Group medical visits (GMVs) can help overcome several of these barriers and effectively improve clinical indicators as well as patients' quality of life. GMVs could also reduce pressure on the healthcare system by improving access to primary care through a more efficient use of resources. The literature suggests that GMVs can be effective in improving access to care and reducing disease complications for patients with several conditions and risk factors, but they have not been assessed specifically among patients with dyslipidemia, which is at the origin of most cases of cardiovascular diseases. In this context, GMVs will be implemented among 144 patients with dyslipidemia. The objective for this project is to evaluate implementation of GMVs. The implementation evaluation will follow the RE-AIM framework. These steps will position the research team to develop more complex and large-scale studies in lifestyle medicine. In the meantime, the project will contribute to improve access to primary care for the prevention of cardiovascular diseases.

Eligibility

Sex

ALL

Min age

40 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Diagnosis of dyslipidemia according to the guidelines of the Canadian Cardiovascular Society, i.e., at a minimum: an intermediate cardiovascular risk according to the Framingham Risk Score (10-19.9%) WITH LDL-C ≥ 3.5 mmol/L or non-HDL-C ≥ 4.2 mmol/L or ApoB ≥ 1.05 g/L Exclusion Criteria: * Patients unable to participate in GMV sessions or to provide informed consent * Patients with a mental health condition likely to limit their ability to benefit from GMV sessions and discussions (Examples: severe dementia or an acute psychiatric decompensation occurring within the past six months) * A diagnosis of terminal illness or a life expectancy of less than 12 months

Primary outcome measure(s)

Lipid profile — 12 months
Low-Density Lipoprotein; High-Density Lipoprotein; Total cholesterol; Triglycerides

Trial sites (1)

Facility	City	Region	Status
Unité de médecine familiale du Grand-Moncton	Dieppe	New Brunswick	Recruiting

More Université de Sherbrooke trials in Canada

Evidence-based Internet Cognitive-behavioral Therapy for Social Anxiety Recruiting

Triple Negative Breast Cancer and Celecoxib. Pilot Study Recruiting

Predicting Breast Cancer With the BRAVE System Recruiting

Health, Imaging, and Cognition Across the Menopausal Transition Starting soon

Outdoor Science Education and Child Well-being in Primary Schools: Protocol for a Cluster Randomized Controlled Trial on Learning, Connection to Nature, Eco-anxiety, and Stress Recruiting

Other trials for the same condition

Using Big Data to Conduct Innovative Cardiovascular Clinical Trials Active, not recruiting

Meta-analyses of Soy Protein and Its Food Sources for Cholesterol Reduction Active, not recruiting

Lipid Testing After Myocardial Infarction at the Montreal Heart Institute Recruiting

Impact of a Regional Program Agir Sur Sa SantE Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07543718 on ClinicalTrials.gov ↗ ← All trials in Canada